UNSPSC 51385616: Aspirin magnesium

This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Mg, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4995924SMK, chemically known as magnesium 2-(acetyloxy)benzoate, but more generally known as aspirin magnesium, which bears US NIH Compound Identifier 8591. European Medicines Agency schedules aspirin magnesium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin magnesium under HS 29182200.

SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[MG+2].

UNSPSC 51385616 Aspirin magnesium is a Commodity code that in recent state and local procurement appears to span generic pharmaceuticals, over-the-counter products, and emergency-response pharmaceuticals supplied through multiple distribution channels to health departments, county health systems, and multistate cooperative purchasing consortia. The code's nominal scope does not align cleanly with the recent opportunities posted under it; the three most recent solicitations involve naloxone and drug deactivation systems (emergency response), direct-to-manufacturer prescription programs (pharmacy benefit management), and generic pharmaceuticals and OTC products through authorized wholesale distributors. State and local buyers under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple states including Oregon). The issuing bodies reflect a mix of direct county procurement, state-level health administration, and cooperative purchasing vehicles that consolidate demand across member jurisdictions.

Recent activity shows geographic concentration in Florida, Texas, and Minnesota, with MMCAP's multistate scope extending to Oregon and other member states. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023—though the posted date and due date appear inconsistent in the source. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. MMCAP released an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awarded vendors effective July 1, 2026. All three opportunities require vendors to meet FDA compliance, supply-chain security certifications, insurance requirements, and electronic ordering or data interchange capabilities.